Conclusions on Treating Carcinoid Crisis Without Perioperative Octreotide for Patients With Neuroendocrine Tumors

Video

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, provides conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.

During the interview, Pommier provided conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Recent Videos
Image credit:  Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
hematological cancer/Image Credit: © nikola-master - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com